Atea Pharmaceuticals reported net income of -$32.93M for the quarter ended Jun 2026. This income statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 83.05M | 83.10M | 83.26M | 83.26M | 83.29M | 83.29M | 83.40M | 83.40M | 83.44M | 83.44M | 84.22M | 84.42M | 84.46M | 84.46M | 85.58M | 81.14M | 78.13M | 78.13M | 80.03M | 80.20M | ||||||||
| Revenue & cost | ||||||||||||||||||||||||||||
| Revenue | 32.81M | 192.18M | ||||||||||||||||||||||||||
| Operating items | ||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 43.02M | 57.81M | 29.63M | 19.86M | 4.91M | 27.54M | 28.95M | 22.06M | 28.18M | 35.05M | 57.58M | 34.70M | 26.16M | 25.67M | 29.58M | 32.27M | 38.35M | 47.82M | 41.13M | 28.15M | ||||||||
| Selling, General & AdministrativeSG&A | 11.94M | 13.19M | 12.54M | 12.44M | 11.38M | 12.36M | 12.62M | 13.17M | 12.60M | 11.53M | 12.23M | 12.22M | 11.04M | 13.36M | 9.46M | 9.07M | 7.22M | 7.12M | 6.87M | 6.95M | ||||||||
| Operating ExpensesOpex | 54.96M | 71.00M | 42.17M | 32.30M | 16.28M | 39.90M | 41.57M | 35.23M | 40.78M | 46.57M | 69.81M | 46.92M | 37.20M | 39.03M | 39.04M | 41.34M | 45.57M | 54.93M | 48.01M | 35.10M | ||||||||
| Operating IncomeOp. Inc | -22.15M | 121.18M | -42.17M | -32.30M | -16.28M | -39.90M | -41.57M | -35.23M | -40.78M | -46.57M | -69.81M | -46.92M | -37.20M | -39.03M | -39.04M | -41.34M | -45.57M | -54.93M | -48.01M | -35.10M | ||||||||
| EBIT | -22.15M | 121.18M | -42.17M | -32.30M | -16.28M | -39.90M | -41.57M | -35.23M | -40.78M | -46.57M | -69.81M | -46.92M | -37.20M | -39.03M | -39.04M | -41.34M | -45.57M | -54.93M | -48.01M | -35.10M | ||||||||
| Non-operating items | ||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.05M | 0.05M | 0.10M | 1.08M | 4.38M | 5.59M | 6.30M | 7.30M | 7.86M | 7.76M | 6.87M | 6.64M | 6.28M | 5.71M | 4.97M | 4.39M | 3.71M | 3.30M | 2.62M | 2.19M | ||||||||
| Net income details | ||||||||||||||||||||||||||||
| EBT | -22.09M | 121.23M | -42.08M | -31.21M | -11.90M | -34.31M | -35.27M | -27.93M | -32.92M | -38.81M | -62.94M | -40.28M | -30.93M | -33.32M | -34.07M | -36.95M | -41.85M | -51.63M | -45.39M | -32.91M | ||||||||
| Tax ProvisionsTaxes | 6.10M | 4.10M | 0.12M | -3.83M | 0.12M | 0.20M | 0.25M | 0.22M | 0.35M | 0.23M | 0.24M | 0.23M | 0.23M | 0.20M | 0.21M | 0.20M | -35.15M | 0.05M | 0.02M | |||||||||
| Profit After TaxPAT | -28.19M | 117.13M | -42.08M | -31.34M | -8.92M | -34.26M | -35.47M | -28.18M | -33.14M | -39.16M | -63.17M | -40.52M | -31.15M | -33.54M | -34.27M | -37.24M | -42.05M | -44.93M | -45.44M | -32.93M | ||||||||
| Income from Continuing OperationsIncome (Continuing) | -28.19M | 117.13M | -42.08M | -31.34M | -8.07M | -34.43M | -35.47M | -28.18M | -33.14M | -39.16M | -63.17M | -40.52M | -31.15M | -33.54M | -34.27M | -37.16M | -42.05M | -16.48M | -45.44M | -32.93M | ||||||||
| Consolidated Net IncomeConsol Net Inc. | -28.19M | 117.13M | -42.08M | -31.34M | -8.07M | -34.43M | -35.47M | -28.18M | -33.14M | -39.16M | -63.17M | -40.52M | -31.15M | -33.54M | -34.27M | -37.16M | -42.05M | -16.48M | -45.44M | -32.93M | ||||||||
| Income towards Parent CompanyParent Net Inc | -28.19M | 117.13M | -42.08M | -31.34M | -8.07M | -34.43M | -35.47M | -28.18M | -33.14M | -39.16M | -63.17M | -40.52M | -31.15M | -33.54M | -34.27M | -37.16M | -42.05M | -16.48M | -45.44M | -32.93M | ||||||||
| Net Income towards Common StockholdersNet Income | -28.19M | 117.13M | -42.08M | -31.34M | -8.07M | -34.43M | -35.47M | -28.18M | -33.14M | -39.16M | -63.17M | -40.52M | -31.15M | -33.54M | -34.27M | -37.16M | -42.05M | -16.48M | -45.44M | -32.93M | ||||||||
| Additional items | ||||||||||||||||||||||||||||
| EPS (Basic) | -0.34 | 1.41 | -0.51 | -0.38 | -0.10 | -0.41 | -0.43 | -0.34 | -0.40 | -0.47 | -0.75 | -0.48 | -0.37 | -0.40 | -0.40 | -0.44 | -0.53 | -0.20 | -0.57 | -0.41 | ||||||||
| EPS (Diluted) | -0.34 | 1.33 | -0.51 | -0.38 | -0.10 | -0.41 | -0.43 | -0.34 | -0.40 | -0.47 | -0.75 | -0.48 | -0.37 | -0.40 | -0.40 | -0.44 | -0.53 | -0.20 | -0.57 | -0.41 | ||||||||
| Shares Outstanding | 82.82M | 82.82M | 83.18M | 83.26M | 83.26M | 83.25M | 83.33M | 83.40M | 83.40M | 83.39M | 83.92M | 84.25M | 84.42M | 84.26M | 85.16M | 83.75M | 79.05M | 81.50M | 79.20M | 80.05M | ||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 82.82M | 88.25M | 83.18M | 83.26M | 83.26M | 83.25M | 83.33M | 83.40M | 83.40M | 83.39M | 83.92M | 84.25M | 84.42M | 84.26M | 85.16M | 83.75M | 79.05M | 81.50M | 79.20M | 80.05M | ||||||||
| EBITDA | -22.15M | 121.18M | -42.17M | -32.30M | -16.28M | -39.90M | -41.57M | -35.23M | -40.78M | -46.57M | -69.81M | -46.92M | -37.20M | -39.03M | -39.04M | -41.34M | -45.57M | -54.93M | -48.01M | -35.10M | ||||||||
| Tax Rate | -27.61 | 3.38 | -0.38 | 32.21 | -0.36 | -0.56 | -0.90 | -0.67 | -0.90 | -0.37 | -0.60 | -0.73 | -0.68 | -0.60 | -0.56 | -0.47 | 68.08 | -0.11 | -0.07 |